<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p185" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_185{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_185{left:306px;bottom:30px;}
#t3_185{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_185{left:346px;bottom:30px;}
#t5_185{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_185{left:517px;bottom:30px;}
#t7_185{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_185{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_185{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_185{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_185{left:35px;bottom:777px;letter-spacing:0.11px;word-spacing:0.07px;}
#tc_185{left:35px;bottom:754px;letter-spacing:0.08px;word-spacing:0.11px;}
#td_185{left:35px;bottom:731px;letter-spacing:0.07px;word-spacing:0.12px;}
#te_185{left:35px;bottom:707px;letter-spacing:0.14px;word-spacing:-1.05px;}
#tf_185{left:35px;bottom:684px;letter-spacing:0.02px;word-spacing:0.16px;}
#tg_185{left:35px;bottom:661px;letter-spacing:0.15px;word-spacing:0.04px;}
#th_185{left:35px;bottom:638px;letter-spacing:0.03px;word-spacing:0.16px;}
#ti_185{left:35px;bottom:614px;letter-spacing:0.06px;word-spacing:0.12px;}
#tj_185{left:35px;bottom:591px;letter-spacing:0.08px;word-spacing:0.11px;}
#tk_185{left:561px;bottom:599px;letter-spacing:-0.01px;}
#tl_185{left:35px;bottom:568px;letter-spacing:0.12px;word-spacing:0.07px;}
#tm_185{left:35px;bottom:545px;letter-spacing:0.04px;word-spacing:-0.46px;}
#tn_185{left:236px;bottom:552px;}
#to_185{left:280px;bottom:545px;letter-spacing:0.13px;word-spacing:-0.77px;}
#tp_185{left:35px;bottom:522px;letter-spacing:0.13px;word-spacing:-0.48px;}
#tq_185{left:35px;bottom:498px;letter-spacing:0.08px;word-spacing:0.1px;}
#tr_185{left:35px;bottom:475px;letter-spacing:0.19px;}
#ts_185{left:287px;bottom:475px;letter-spacing:0.14px;word-spacing:0.04px;}
#tt_185{left:35px;bottom:452px;letter-spacing:0.08px;word-spacing:0.11px;}
#tu_185{left:35px;bottom:413px;letter-spacing:0.31px;}
#tv_185{left:35px;bottom:383px;letter-spacing:0.11px;word-spacing:0.08px;}
#tw_185{left:35px;bottom:360px;letter-spacing:0.09px;word-spacing:-1.13px;}
#tx_185{left:260px;bottom:360px;letter-spacing:0.13px;word-spacing:-0.29px;}
#ty_185{left:35px;bottom:337px;letter-spacing:0.09px;word-spacing:0.1px;}
#tz_185{left:35px;bottom:314px;word-spacing:0.19px;}
#t10_185{left:35px;bottom:291px;letter-spacing:0.07px;word-spacing:0.12px;}
#t11_185{left:35px;bottom:267px;letter-spacing:0.05px;word-spacing:-0.69px;}
#t12_185{left:35px;bottom:244px;letter-spacing:0.14px;word-spacing:-1.01px;}
#t13_185{left:384px;bottom:244px;letter-spacing:0.08px;word-spacing:0.1px;}
#t14_185{left:523px;bottom:244px;}
#t15_185{left:533px;bottom:244px;letter-spacing:0.08px;}
#t16_185{left:35px;bottom:221px;letter-spacing:0.15px;word-spacing:0.03px;}
#t17_185{left:35px;bottom:178px;letter-spacing:-0.14px;word-spacing:1px;}
#t18_185{left:35px;bottom:150px;letter-spacing:0.05px;word-spacing:-0.98px;}
#t19_185{left:35px;bottom:128px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1a_185{left:35px;bottom:105px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1b_185{left:35px;bottom:82px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1c_185{left:35px;bottom:58px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1d_185{left:618px;bottom:777px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1e_185{left:618px;bottom:754px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1f_185{left:618px;bottom:731px;letter-spacing:0.11px;word-spacing:-0.13px;}
#t1g_185{left:618px;bottom:707px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1h_185{left:618px;bottom:684px;letter-spacing:0.08px;word-spacing:-0.76px;}
#t1i_185{left:618px;bottom:661px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1j_185{left:618px;bottom:638px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1k_185{left:618px;bottom:614px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_185{left:618px;bottom:591px;letter-spacing:0.04px;word-spacing:-0.83px;}
#t1m_185{left:618px;bottom:568px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1n_185{left:618px;bottom:529px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t1o_185{left:618px;bottom:500px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t1p_185{left:618px;bottom:476px;letter-spacing:0.05px;word-spacing:-0.67px;}
#t1q_185{left:854px;bottom:476px;letter-spacing:0.15px;word-spacing:-1.2px;}
#t1r_185{left:1068px;bottom:476px;letter-spacing:-0.31px;}
#t1s_185{left:1100px;bottom:476px;letter-spacing:0.06px;word-spacing:-1.11px;}
#t1t_185{left:618px;bottom:453px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1u_185{left:802px;bottom:453px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1v_185{left:618px;bottom:430px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1w_185{left:618px;bottom:407px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1x_185{left:618px;bottom:383px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1y_185{left:820px;bottom:383px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t1z_185{left:618px;bottom:360px;letter-spacing:0.19px;}
#t20_185{left:749px;bottom:360px;letter-spacing:0.12px;word-spacing:0.07px;}
#t21_185{left:618px;bottom:337px;letter-spacing:0.09px;word-spacing:0.1px;}
#t22_185{left:924px;bottom:345px;letter-spacing:0.61px;}
#t23_185{left:939px;bottom:337px;letter-spacing:0.1px;word-spacing:0.08px;}
#t24_185{left:618px;bottom:314px;letter-spacing:0.16px;word-spacing:0.03px;}
#t25_185{left:618px;bottom:291px;letter-spacing:0.07px;word-spacing:0.11px;}
#t26_185{left:618px;bottom:267px;letter-spacing:0.16px;word-spacing:0.03px;}
#t27_185{left:928px;bottom:275px;letter-spacing:-0.01px;}
#t28_185{left:618px;bottom:227px;letter-spacing:0.2px;}
#t29_185{left:618px;bottom:199px;letter-spacing:0.09px;word-spacing:-0.69px;}
#t2a_185{left:618px;bottom:176px;letter-spacing:0.16px;word-spacing:-0.55px;}
#t2b_185{left:618px;bottom:152px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2c_185{left:618px;bottom:112px;letter-spacing:0.08px;word-spacing:-0.02px;}
#t2d_185{left:618px;bottom:89px;letter-spacing:0.14px;word-spacing:-1.18px;}
#t2e_185{left:1139px;bottom:96px;letter-spacing:-0.92px;}
#t2f_185{left:618px;bottom:66px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2g_185{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_185{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_185{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_185{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_185{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_185{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_185{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_185{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_185{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_185{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_185{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts185" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg185Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg185" style="-webkit-user-select: none;"><object width="1210" height="935" data="185/185.svg" type="image/svg+xml" id="pdf185" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_185" class="t s0_185">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_185" class="t s1_185">© </span>
<span id="t3_185" class="t s0_185">(NCCN </span>
<span id="t4_185" class="t s1_185">© </span>
<span id="t5_185" class="t s0_185">), All rights reserved. NCCN Guidelines </span>
<span id="t6_185" class="t s1_185">® </span>
<span id="t7_185" class="t s0_185">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_185" class="t s2_185">NCCN Guidelines Version 4.2024 </span>
<span id="t9_185" class="t s2_185">Head and Neck Cancers </span>
<span id="ta_185" class="t s3_185">MS-44 </span>
<span id="tb_185" class="t s4_185">complications were also less frequent in the hyperfractionation arm. It </span>
<span id="tc_185" class="t s4_185">should be noted that, in this trial, hyperfractionation was not actually </span>
<span id="td_185" class="t s4_185">compared to standard fractionation, as the control arm of 60 Gy was </span>
<span id="te_185" class="t s4_185">delivered at 2.22 Gy/day, which is considered slightly hypofractionated for </span>
<span id="tf_185" class="t s4_185">NPC. Nonetheless, because tolerability and late complications are a </span>
<span id="tg_185" class="t s4_185">frequent concern associated with reirradiation, hyperfractionation to a </span>
<span id="th_185" class="t s4_185">lower total physical dose has high appeal as an attractive option for </span>
<span id="ti_185" class="t s4_185">patients who are able to manage this rigorous twice-daily schedule. </span>
<span id="tj_185" class="t s4_185">Recommendations regarding NPC reirradiation have been published, </span>
<span id="tk_185" class="t s5_185">567 </span>
<span id="tl_185" class="t s4_185">and reports describe a variety of technical approaches including IMRT, </span>
<span id="tm_185" class="t s4_185">SBRT, and brachytherapy. </span>
<span id="tn_185" class="t s5_185">568-570 </span>
<span id="to_185" class="t s4_185">In general, a fractionated course of IMRT </span>
<span id="tp_185" class="t s4_185">in combination with concurrent chemotherapy is the most frequently used </span>
<span id="tq_185" class="t s4_185">approach when the intent remains curative, with SBRT or more highly </span>
<span id="tr_185" class="t s4_185">hypofractionated schedules (eg, </span><span id="ts_185" class="t s6_185">≥3 Gy/fraction) being more commonly </span>
<span id="tt_185" class="t s4_185">used in cases of palliative intent. </span>
<span id="tu_185" class="t s3_185">Follow-up/Surveillance </span>
<span id="tv_185" class="t s4_185">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="tw_185" class="t s7_185">Follow-up Recommendations </span><span id="tx_185" class="t s4_185">in the NCCN Guidelines for Head and Neck </span>
<span id="ty_185" class="t s4_185">Cancers). Since the deep areas of the skull base are inaccessible to </span>
<span id="tz_185" class="t s4_185">clinical examination, periodic cross-sectional imaging may be necessary. </span>
<span id="t10_185" class="t s4_185">Likewise, inspection of the nasopharyngeal mucosa may be best </span>
<span id="t11_185" class="t s4_185">accomplished with periodic endoscopy. The clinical benefit of plasma EBV </span>
<span id="t12_185" class="t s4_185">DNA monitoring is not yet clearly defined (see </span><span id="t13_185" class="t s7_185">Epstein-Barr Virus</span><span id="t14_185" class="t s4_185">, </span><span id="t15_185" class="t s4_185">above), </span>
<span id="t16_185" class="t s4_185">but it may be considered in centers with experience (category 2B). </span>
<span id="t17_185" class="t s8_185">Cancer of the Larynx </span>
<span id="t18_185" class="t s4_185">The larynx is divided into three regions: supraglottis, glottis, and subglottis. </span>
<span id="t19_185" class="t s4_185">The distribution of cancers is as follows: 30% to 35% in the supraglottic </span>
<span id="t1a_185" class="t s4_185">region, 60% to 65% in the glottic region, and 5% in the subglottic region. </span>
<span id="t1b_185" class="t s4_185">The incidence and pattern of metastatic spread to regional nodes vary with </span>
<span id="t1c_185" class="t s4_185">the primary region. The lymphatic drainage of the glottis is sparse and </span>
<span id="t1d_185" class="t s4_185">early-stage primaries rarely spread to regional nodes. Because </span>
<span id="t1e_185" class="t s4_185">hoarseness is an early symptom, most glottic cancers are early stage at </span>
<span id="t1f_185" class="t s4_185">diagnosis. Thus, glottic cancer has an excellent cure rate of 80% to 90%. </span>
<span id="t1g_185" class="t s4_185">Nodal involvement adversely affects survival rates and is rare in T1–2 </span>
<span id="t1h_185" class="t s4_185">disease. In contrast, more than 50% of patients with supraglottic primaries </span>
<span id="t1i_185" class="t s4_185">present with spread to regional nodes because of an abundant lymphatic </span>
<span id="t1j_185" class="t s4_185">network that crosses the midline. Bilateral cervical metastases are not </span>
<span id="t1k_185" class="t s4_185">uncommon with early-stage supraglottic primaries. Thus, supraglottic </span>
<span id="t1l_185" class="t s4_185">cancer is often metastatic and higher stage at diagnosis. Subglottic cancer </span>
<span id="t1m_185" class="t s4_185">is not discussed, because it is uncommon. </span>
<span id="t1n_185" class="t s3_185">Workup and Staging </span>
<span id="t1o_185" class="t s4_185">The evaluation of the patient to determine tumor stage is similar for glottic </span>
<span id="t1p_185" class="t s4_185">and supraglottic primaries (see </span><span id="t1q_185" class="t s7_185">Cancer of the Glottic Larynx </span><span id="t1r_185" class="t s4_185">and </span><span id="t1s_185" class="t s7_185">Cancer of </span>
<span id="t1t_185" class="t s7_185">the Supraglottic Larynx </span><span id="t1u_185" class="t s4_185">in the NCCN Guidelines for Head and Neck </span>
<span id="t1v_185" class="t s4_185">Cancers). Multidisciplinary consultation is frequently indicated for both </span>
<span id="t1w_185" class="t s4_185">sites because of the potential impact on voice quality, speech, and </span>
<span id="t1x_185" class="t s4_185">swallowing functions (see </span><span id="t1y_185" class="t s7_185">Principles of Nutrition: Management and </span>
<span id="t1z_185" class="t s7_185">Supportive Care </span><span id="t20_185" class="t s4_185">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t21_185" class="t s4_185">The 2017 AJCC staging classification (8 </span>
<span id="t22_185" class="t s5_185">th </span>
<span id="t23_185" class="t s4_185">edition) for laryngeal primary </span>
<span id="t24_185" class="t s4_185">tumors is determined by the number of subsites involved, vocal cord </span>
<span id="t25_185" class="t s4_185">mobility, the presence of metastases, extranodal extension, and invasion </span>
<span id="t26_185" class="t s4_185">of thyroid/cricoid cartilage (see Table 5). </span>
<span id="t27_185" class="t s5_185">391 </span>
<span id="t28_185" class="t s3_185">Treatment </span>
<span id="t29_185" class="t s4_185">In the NCCN Guidelines, the treatment of patients with laryngeal cancer is </span>
<span id="t2a_185" class="t s4_185">divided into two categories: 1) tumors of the glottic larynx; or 2) tumors of </span>
<span id="t2b_185" class="t s4_185">the supraglottic larynx. </span>
<span id="t2c_185" class="t s4_185">For patients with carcinoma in situ of the larynx, recommended treatment </span>
<span id="t2d_185" class="t s4_185">options include: 1) endoscopic resection, which is preferred; or 2) RT. </span>
<span id="t2e_185" class="t s5_185">571,572 </span>
<span id="t2f_185" class="t s4_185">For early-stage glottic or supraglottic cancer, a systematic review </span>
<span id="t2g_185" class="t s9_185">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
